Urinary Tract Infection News and Research RSS Feed - Urinary Tract Infection News and Research

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.
FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis. [More]
Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules. [More]
Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Actavis South Atlantic LLC and Actavis, Inc. (collectively, "Actavis") to resolve pending patent litigation in response to Actavis' abbreviated new drug application seeking approval to market generic versions of Avanir's NUEDEXTA (dextromethorphan hydrobromide/quinidine sulfate) capsules. [More]
Physicians and health professionals need to be on alert for caregiver-fabricated illness in children

Physicians and health professionals need to be on alert for caregiver-fabricated illness in children

While it's rare for a parent to fabricate an illness in their child, a McMaster University researcher says physicians and other health professionals need to be on the alert for this form of child abuse. [More]
Risk of kidney stones increasing among women

Risk of kidney stones increasing among women

The risk of women developing kidney stones is rising, as is the number of cases being seen in U.S. emergency departments, while the rate of hospitalization for the disorder has remained stable. [More]

Health professionals need to be alert for fabricated illness in child, says researcher

While it's rare for a parent to fabricate an illness in their child, a McMaster University researcher says physicians and other health professionals need to be on the alert for this form of child abuse. [More]
Multiple hospitalizations for complications from terminal illness burdensome for older patients

Multiple hospitalizations for complications from terminal illness burdensome for older patients

"Multiple hospitalizations for complications from a terminal illness may be burdensome for elderly patients and reflect poor quality care," write Joan M. Teno, M.D., M.S., of the Warren Alpert School of Medicine of Brown University, Providence, R.I., and colleagues, who conducted a study to examine whether the occurrence of multiple hospitalizations for the complications of infections or dehydration was associated with survival. [More]
Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). [More]
Solution-based circuit chip for rapid, multiplexed detection of pathogens

Solution-based circuit chip for rapid, multiplexed detection of pathogens

Life-threatening bacterial infections cause tens of thousands of deaths every year in North America. Increasingly, many infections are resistant to first-line antibiotics. Unfortunately, current methods of culturing bacteria in the lab can take days to report the specific source of the infection, and even longer to pinpoint the right antibiotic that will clear the infection. [More]
Mid-stream urine collection system: an interview with Giovanna Forte, Managing Director, Forte Medical

Mid-stream urine collection system: an interview with Giovanna Forte, Managing Director, Forte Medical

The mid-stream (MSU) is urine from the bladder, which carries the information clinicians need to accurately identify and diagnose a UTI, or in the case of antenatal patients, make sure all is well. [More]
FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older. [More]

Primary health care for patients with urinary tract infections can save nearly $4 billion in ER visits

Giving patients better access to primary health care could save nearly $4 billion a year in unnecessary emergency room visits for a single common complaint - urinary tract infections - according to a study by the Vattikuti Urology Institute at Henry Ford Hospital in Detroit. [More]
Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA). [More]

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler. [More]

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause. [More]
Schizophrenia patients experiencing relapse are more likely to develop UTIs

Schizophrenia patients experiencing relapse are more likely to develop UTIs

Schizophrenia patients experiencing relapse are 29 times more likely than healthy individuals to have a urinary tract infection, researchers report. [More]
Invokana tablets receive FDA approval to treat adults with type 2 diabetes

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

The U.S. Food and Drug Administration today approved Invokana (canaglifozin) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes. [More]

Patients at Michigan hospitals less likely to experience catheter-associated UTIs: Study

Patients at Michigan hospitals are less likely to experience a urinary tract infection caused by a catheter than at other hospitals in the country, according to a new study by the University of Michigan. [More]
Study: Flagellin plays a critical role in regulating host innate defences against UTIs

Study: Flagellin plays a critical role in regulating host innate defences against UTIs

A new study by British scientists reveals that motile Escherichia coli isolates demonstrated significant activation of NF-κB signaling suggesting that flagellin plays a key role in up-regulating the host innate defences against urinary tract infections (UTIs). [More]
ST131 infection is more prevalent in LTCF residents and elderly population

ST131 infection is more prevalent in LTCF residents and elderly population

Antibiotic-resistant Escherichia coli (E. coli) continues to proliferate, driven largely by expansion of a strain of E. coli know as sequence type ST131. A new study points to hospitals and long-term care facilities (LTCF) as settings in which this antibiotic-resistant strain is increasingly found. [More]